RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Pieris Pharmaceuticals Stock

Pieris Pharmaceuticals ROCE 2024

Pieris Pharmaceuticals ROCE

-0.59

Ticker

PIRS

ISIN

US7207951036

WKN

A12G4Q

In 2024, Pieris Pharmaceuticals's return on capital employed (ROCE) was -0.59, a -61.96% increase from the -1.56 ROCE in the previous year.

Pieris Pharmaceuticals Aktienanalyse

What does Pieris Pharmaceuticals do?

Pieris Pharmaceuticals Inc is a biotechnology company that focuses on the development of therapeutic antibodies. The company was founded in 2001 in Freising, Germany, and has since relocated its headquarters to Boston, USA. The company's history traces back to the research group of Professor Arne Skerra at the Technical University of Munich, which specialized in the development of new protein engineering technologies. Together with another biotech company, Swiss CYTHERIS SA, they eventually founded Pieris Pharmaceuticals Inc. The company received $10 million in funding in 2004 from international investors, including some German funds. Since then, the company has had several successful IPOs and has become one of the leading biotech companies in antibody research. The business model of Pieris Pharmaceuticals is based on the development and commercialization of antibodies that can be used as therapeutics for various diseases. The company combines its own research and development efforts with partnerships with other companies and organizations. The company's divisions include the development of antibodies for the treatment of cancer and immune-related diseases, the development of antibodies to combat infectious diseases, and the development of novel antibody platforms to generate broad antibody spectra. One of Pieris Pharmaceuticals' most successful products is the antibody PRS-343, which was developed as a therapeutic for HER2-positive breast cancer. A study showed that PRS-343, in combination with the chemotherapy drug Herceptin, has a higher efficacy than Herceptin alone. Another promising project is the development of an antibody for the treatment of tumors in the gastrointestinal tract. The substance PRS-276 is able to selectively attack and kill these cells due to its high affinity to the tumor antigen Claudin18.2. Overall, Pieris Pharmaceuticals Inc has launched numerous successful projects in recent years and has expanded its competitive position in the biotech industry. The company aims to closely collaborate with partners from the pharmaceutical industry to accelerate and optimize the development and commercialization of its products. Pieris Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Pieris Pharmaceuticals's Return on Capital Employed (ROCE)

Pieris Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Pieris Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Pieris Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Pieris Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Pieris Pharmaceuticals stock

What is the ROCE (Return on Capital Employed) of Pieris Pharmaceuticals this year?

The ROCE of Pieris Pharmaceuticals is -0.59 undefined this year.

How has the ROCE (Return on Capital Employed) of Pieris Pharmaceuticals developed compared to the previous year?

The ROCE of Pieris Pharmaceuticals has increased by -61.96% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Pieris Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that Pieris Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Pieris Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that Pieris Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Pieris Pharmaceuticals impact the company?

An increase in the ROCE of Pieris Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Pieris Pharmaceuticals affect the company?

A decrease in ROCE of Pieris Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Pieris Pharmaceuticals?

Some factors that can affect Pieris Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Pieris Pharmaceuticals so important for investors?

The ROCE of Pieris Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Pieris Pharmaceuticals take to improve the ROCE?

To improve the ROCE, Pieris Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Pieris Pharmaceuticals pay?

Over the past 12 months, Pieris Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pieris Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Pieris Pharmaceuticals?

The current dividend yield of Pieris Pharmaceuticals is .

When does Pieris Pharmaceuticals pay dividends?

Pieris Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pieris Pharmaceuticals?

Pieris Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Pieris Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pieris Pharmaceuticals located?

Pieris Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pieris Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pieris Pharmaceuticals from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Pieris Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Pieris Pharmaceuticals in the year 2023?

In the year 2023, Pieris Pharmaceuticals distributed 0 USD as dividends.

In which currency does Pieris Pharmaceuticals pay out the dividend?

The dividends of Pieris Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Pieris Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Pieris Pharmaceuticals

Our stock analysis for Pieris Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pieris Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.